The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD

A Randomized, Double-Blinded, Placebo-Controlled Trial To Assess The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With Treatment Refractory Major Depressive Disorder

To determine if the NMDA antagonist, CP-101,606, is effective for depression

Inclusion Criteria:

• Primary DSM-IV diagnosis of MDD

Exclusion Criteria:

• Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).